Skip to content 
AMM 160: XEOMIN Approved for Comprehensive Facial Treatment
August 05, 2024
This episode explores a key moment in medical aesthetics: the FDA’s approval of XEOMIN® (incobotulinumtoxinA) for the simultaneous treatment of forehead lines, frown lines, and crow’s feet. Initially approved in 2011 for frown lines, XEOMIN® now expands its scope, offering a comprehensive solution for upper facial lines. Hear from Merz Aesthetics’ Chief Scientific Officer, Dr. Samantha Kerr, and President of North America, Patrick Urban, about the product’s unique formulation and the technology behind its effectiveness. Celebrity endorsement by Demi Lovato underscores XEOMIN®’s appeal for natural-looking, lasting results. This episode provides insights into the clinical studies validating its safety and efficacy and shares information on how to find a provider. Tune in to understand what this means for the future of facial aesthetics.
Quick Takes
- Merz Aesthetics received FDA approval for XEOMIN® as the first neurotoxin for the simultaneous treatment of upper facial lines.
- This approval expands XEOMIN®’s treatment portfolio to include forehead lines, frown lines, and crow’s feet.
- XEOMIN® now contains essential ingredients, preferred by consumers, and utilizes XTRACT Technology™ to enhance effectiveness and reduce immune responses.
Episode Transcript
In today’s episode, we delve into a significant milestone in the realm of medical aesthetics. On August 5th, 2024, Merz Aesthetics announced a groundbreaking development: the U.S. Food and Drug Administration has approved XEOMIN® (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines. This includes forehead lines, frown lines, and crow’s feet, broadening the scope of cosmetic treatments available today.
A name that’s already familiar within the pharmaceutical circles, XEOMIN® initially received FDA approval in 2011 for the treatment of moderate to severe frown lines. This latest approval is a progression from its earlier indications, adding horizontal forehead lines and lateral canthal lines to its treatment portfolio. It’s a pivotal enhancement for those seeking comprehensive aesthetic solutions.
Chief Scientific Officer at Merz Aesthetics, Dr. Samantha Kerr, highlighted that XEOMIN® now contains only essential ingredients needed for treatment which, based on recent surveys, is overwhelmingly preferred by consumers. Patrick Urban, President of North America for Merz Aesthetics, also pointed out the proprietary XTRACT Technology™ used in XEOMIN®, which filters out unnecessary proteins that could otherwise trigger immune responses and diminish the effectiveness of the treatment.
Moreover, the approval was propelled into the spotlight with the endorsement of Demi Lovato, who is partnering with the ‘Beauty on Your Terms’ campaign by Merz Aesthetics. Lovato praises XEOMIN® for the natural-looking results that are consistent through her treatments, emphasizing the brand’s innovative approach to aesthetics.
The clinical studies bolstering this approval demonstrated that XEOMIN® is safe and effective, showing significant results over placebo at Day 30 post-treatment, with benefits maintained across multiple sessions over 14 months. Indeed, this isn’t just a win for Merz Aesthetics but for potential users seeking reliable and lasting solutions in facial aesthetics.
Stay tuned for more updates, and remember, today’s aesthetics news could be the fresh face of tomorrow!
